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Abstract
The aim of this study was to characterize the T lymphocyte phenotype and phospho-
rylated axonal neurofilament subunit H (pNF-H) in dogs diagnosed with progressive 
myelomalacia (PM) and dogs with presumptive PM. A retrospective case series of six dogs 
with confirmed PM and 8 dogs with presumptive PM was in vesrigared, conducted and 
clinical signs, magnetic resonance imaging (MRI), the somatosensory evoked potential, and 
T lymphocyte phenotype in clinical records and pNF-H levels in the peripheral blood were 
evaluated. pNF-H levels were determined in both study dogs and healthy controls 
(beagles). PM was clinically diagnosed based on: (Berger et al. 2007) MRI of disc-
associated spinal cord compression, (Boylan et al. 2009) clinical progression from initial 
paraparesis or paraplegia, to thoracic limb lower motor neuron paresis, to tetraplegia 
associated with cranial migration to the extent of cutaneous trunci reflex loss and 
analgesia, leading to death via respiratory paralysis, and (Ceron et al. 2005) histological 
examination. All PM dogs were paraplegic and had signs of lower motor neuron lesions. 
The  CD4±/CD8+ ratio in 13 out of the 14 dogs (92.9%) was significantly higher than that in 
healthy controls (p < 0.001). pNF-H was only detected in the peripheral blood of PM dogs. 
In some PM dogs, we did not observe signal hyperintensity on T2-weighted MRI. Our 
study results indicate that the detection of pNF-H and a high  CD4+  /CD8  + ratio in the 
peripheral blood may Facilitate earlier diagnosis of PM than is possible with MRI.
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Introduction
 Currently, the pathogenic mechanism of canine 
progressive myelomalacia (PM) remains  un-
known, and no effective treatment is available. 
Affected individuals typically die of respiratory 
failure within several days of symptom onset 
(Okada et al. 2010). PM, which does not occur in 
humans, has become one of the most important
spinal disorders in dogs and has been reported in 
approximately 10% of dogs suffering from tho-
racolumbar Intervertebral disc herniation (IVDH), 
featuring a loss of pain perception (Olby et al. 
2003; Scott et al. 1999). The symptoms associated 
with canine thoracolumbar IVDH are typically 
classified into 5 stages: pain with no other symp-
toms (Grade 1), ambulatory paresis (Grade 2), non-
ambulatory paresis (Grade 3), paraplegia (Grade 4),
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and paraplegia with loss of nociception (Grade 5) 
(Schulz et al.1998). Symptom severity is depend-
ent on the extent and degree of compression and 
damage to the spinal cord. Because PM does not 
manifest in dogs suffering from thoracolumbar 
IVDH without paraplegia, canine PM is thought to 
be a feature only in severe cases of IVDH (i. e., not 
observed in Grades 1 to 3). 
 The degree of spinalcord injury can vary in 
Hansen type I disc herniation, which appears in 
dogs as an acute protrusion of the nucleus into the 
spinal canal. Acute spinal cord injury is divided 
into primary and secondary injuries. Primary in-
jury is caused by direct physical or mechanical 
pressure exerted onto the neurons and blood  ves-
sels by prolapse of the nucleus pulposus. The se-
verity of the primary lesion is dependent on the 
speed and volume of the nucleus pulposus pro-
truding into the spinal canal as well as the extent 
and duration of spinal cord compression (Scott et 
al. 1999). Spinal cord ischemia caused by primary 
injury can induce a reaction cascade that  pri-
marily involves tissue-damaging biochemical 
changes, which, in turn, can lead to secondary 
injury. Within 10 to 20 minutes after spinal cord 
injury, minor bleeding spots develop due to in-
creased vascular permeability. Within hours, the 
appearance of edema, ischemia, hemorrhagic foci 
in the gray and white matter, failure of local mi-
crocirculation, and a lack of nutrients and oxygen 
result in the progressive necrosis of neurons in 
the vicinity. Additionally, as soon as the microcir-
culation fails (minutes after injury), the continuous 
overproduction of free radicals, the excitatory 
neurotransmitter glutamine, and inflammatory 
cytokines for several weeks thereafter leads to 
further tissue damage, including apoptosis (Saiwai 
et al. 2010). The cytokines are produced by the 
neurons and astrocytes themselves and by 
neutrophils and macrophages that migrate from 
the vascular system upon the breakdown of the 
blood-spinal cord barrier (Gonzalez et al. 2003). 
Although it is likely that changes in the injured 
spinal cord microenvironment result in PM 
development and lesion expansion, the mecha-
nism underlying this process has not yet been 
elucidated, and no effective treatment is available 
for PM. 
 In PM dogs presenting with severe IVDH, sur-
gical extraction of the protruded disc material is 
not an effective means for preventing disease 
progression, and it inevitably results in death. 
Nevertheless, early surgery remains the primary 
intervention for severe cases of IVDH in dogs, and 
this is where practicing veterinarians face difficul-
ty  in treatment. 
 The number of reports available on clinical 
cases and studies of canine PM is extremely 
limited. In this study, we explored the possible 
correlations between PM and the results obtained 
from electrophysiological testing and magnetic 
resonance imaging (MRI) in addition to a new 
approach that involves Phosphorylated axonal 
neurofilament subunit H (pNF-H) analysis along 
with an examination of the T lymphocyte pheno-
type. These evaluations were conducted in 14 
dogs that were presumed or confirmed to have 
incurable PM.
Materials and Methods
Case selection 
 The study was conducted involving 14 dogs 
diagnosed with acute paraplegia at Aikouishida 
Animal Hospital from January 2009 to March 2012 
that were later presumed or confirmed to have 
PM. A presumptive diagnosis of PM was made 
based on clinical symptoms from initial paraplegi-
a, to thoracic limb lower motor neuron (LMN) 
paresis to tetraplegia associated with cranial mi-
gration to the extent of cutaneous trunci muscle 
reflex loss, leading to death due to respiratory 
paralysis, in accordance with a report by Okada et 
al. (2010). A definitive diagnosis of PM was made 
based on histopathological findings in cases in 
which necropsy was consented to. Where PM 
was strongly suspected, euthanasia was recom-
mended because of the poor prognosis associated 
with this disease. 
 The study was performed in accordance with 
the Japanese Regulations for Animal Welfare 
issued by The Ministry of Education, Culture, 
Sports, Sciences, and Technology of Japan.
Medical records review 
 The following parameters were obtained from 
the medical records of each dog: breed, age, sex, 
body weight, clinical findings from a neurologic 
examination, existence of pelvic limb nociception 
prior to MRI examination, existence of vertebral 
column hyperesthesia, interval between onset of 
clinical signs and signs of LMN lesions in the 
pelvic limbs or cranial migration of the neurologic 
deficits, interval between onset of clinical signs 
and MRI examination, existence of  Horner syn-
drome, and interval from the onset of clinical signs 
to death.
C-reactive protein measurement 
 The C-reactive protein (CRP) level was mea-
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sured with immunonephelometry (Laser CRP-2, 
Arrows, Osaka, Japan) using 30  /21, of serum. The 
range of measurement was set as 0.05-20 mg/dL.
Flow cytometric analysis of peripheral blood 
 The analysis was performed in rolring on 14 
dogs with PM and 6 healthy beagles. The relative 
ratios (Accuri C6 flow cytometer, Accuri Cyto-
meters Inc., MI, USA ) of CD3+ (Tcells), CD4+ 
(helper Tcells), CD8+ (cytotoxic Tcells), and 
CD21+ (Bcells) were obtained against the canine-
specific antibodies listed in Table 3. 
 Blood samples (200  L) were mixed with 2   L of 
lysis solution (FACS lysis solution, Becton, 
Dickinson and Company, NJ, USA) and incubated 
for 15 minutes at room temperature. Peripheral 
WBCs (white blood cells) were isolated  by 
centrifugation (200 g) for 5 minutes at room tem-
perature. The WBC (white blood cell) fraction 
was rinsed before a sufficient amount of antibody 
(Antibodies, Serotec, Oxford, UK) was added. The 
samples were incubated in the dark for 15  min-
utes at room temperature. A suitable antibody 
concentration was calculated beforehand. 
 Once the reaction was complete, 2 mL of 
phosphate-buffered saline solution was added to 
remove the excess primary antibody. Finally, the 
cells were suspended in 500   L of sheath fluid 
 (FACSFlow, Becton, Dickinson and Company, NJ, 
USA) and maintained at 4°C until analysis (CFlow 
Plus software, Accuri Cytometers Inc., MI, USA). 
The cell phenotypes of peripheral lymphocytes 
were obtained by gating on the screen with a 
forward scatter versus side scatter dot plot 
(FACSCalibur, Becton, Dickinson and Company, 
NJ, USA). For each sample, data from 5,000 
events in the lymphocyte gates were recorded, 
from which the percentages of  CD3+  CD4 
 CD8  +, and CD21 + were categorized according to 
the different lymphocyte surface markers over 
the 5,000 events. The absolute values for the 
lymphocyte subsets were calculated using counts 
obtained from WBC analysis in combination with 
the flow cytometer. These procedures were con-
ducted in accordance with Tamura et al. (2012).
Quantification of serum pNF-H levels 
 Serum samples were obtained from 6 healthy 
beagles (controls) that were purchased for other 
purposes and 14 PM dogs and were stored at 
— 30°C . The assay was performed using a com-
mercial ELISA kit (ELISA-pNFH; BioVendor 
Laboratory Medicine Inc., Brno, Czech Republic). 
Frozen serum samples were thawed, and the 
samples obtained from each specimen were load-
ed onto an ELISA plate. The assay was per-
formed according to the manufacturer's protocol.
Neurologic examination 
 Examinations consisted of tests to assess pos-
turad responses (proprioception, placing reaction, 
hopping reaction, and extensor postural thrust), 
spinal reflexes (patellar eflex, cranial tibial reflex, 
gastrocnemius reflex, flexion reflex, crossed-
extension reflex, and panniculus reflex), nocicep-
tion, and the animals' ability to self-urinate.
Diagnostic imaging 
 T1  (Tl-weighted magnetic resonance imaging) 
— and T2 (T2-weighted magnetic resonance 
imaging)  — weighted MRI (0.2 T Vet-MR, Esaote 
S. p. A, Genova, Italy) wase performed under gen-
eral  anesthesia. The findings were reviewed by 3 
veterinarians until an agreement was reached 
regarding the MRI interpretations (including the 
site and side of IVDH and the locations of abnor-
mal signal intensities within the spinal cord). Ab-
normal signal intensities within the spinal cord 
were characterized as hyperintense, isointense, or 
hypointense compared with healthy spinal cord 
parenchyma on sagittal and transverse T1WI and 
T2WI. The lengths of the abnormal signal intensi-
ties were measured in comparison with the body 
length of L2.
Somatosensory evoked potential 
 The somatosensory evoked potential test was 
performed under general anesthesia with iso-
flurane. Somatosensory evoked potential (SEP) 
was measured with a system (Neuropack MEB-
9102, Nihon Koden, Tokyo, Japan) that adopts 
surface-disc electrodes as recording and reference 
electrodes. The recording electrode was placed 
at the juncture of the coronal and sagittal sutures, 
which was considered to be adjacent to the 
somatosensory area, and the reference electrode 
was placed on the spinous process of the axis 
following the method of Uzuka et al. (1995). Elec-
trical stimulation was applied at a frequency of 3 
Hz for 0.2 milliseconds to obtain an average total 
of 500 responses according to the method de-
scribed by Okuno et al. (2005).
Statistical analyses 
 The significance of the values was determined 
using the Mann-Whitney  U-test and other statisti-
cal analyses (StatMate III for Windows, Atms, 
Tokyo, Japan). Values with  PC  0.001 were con-
sidered significant.
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Results
Dogs 
 This study was conducted using 14 dogs (8 
males and 6 females): including 12 miniature 
dachshunds, one French bulldog, and one  Ameri-
can cocker spaniel (Table 1). The mean age of the 
dogs was  5.42  ±  2.9 years, and that of the body 
weight was  6.22  ±  3.0 kg  (mean  ±  SD).
Clinical signs 
 The chief complaint in all dogs was the sudden 
onset of paraplegia. Eleven of the 14 dogs had 
developed paraplegia within 12 hours of the onset 
of symptoms including discomfort, anorexia, or 
paraparesis at the owner properties, and the re-
maining dogs had developed paraplegia 24 hours 
after the onset of  paraparesis. The body tempera-
ture was  39.5°C in 3 of the 14 dogs. High CRP 
levels (over 1.0 mg/dL) were observed in 2 of the 
14 dogs. In 3 of the 14 dogs, the WBS counts were 
higher than 20,000  cells/ L. According to their 
clinical histories, each dog lacked nociception in 
the pelvic limbs at the time of referral for evalua-
tion. All dogs eventually developed LMN signs in 
the pelvic limbs, cranial migration of neurologic 
deficits,  or both. Eight of the 14 dogs developed
bilateral  Horner syndrome on the day prior to 
their death (Table 2). The mean duration from 
the onset of PM until death was 7.43  ± 2.9 days 
 (mean  ±  SD). Ten dogs died due to disease pro-
gression, and the remaining dogs were eutha-
nized.
Diagnosis 
 A definitive diagnosis of PM was made in 6 
dogs. This sample included 4 dogs that were 
euthanized and 2 dogs that died naturally from 
disease progression. A pathological diagnosis was 
made during post-mortem examination with con-
sent from each owner. The remaining 8 dogs 
were presumed to have PM based on findings that 
were consistent with the case definition.
Magnetic resonance imaging 
 The median interval from the onset of clinical 
signs to MRI was 2.0 days (range: 1 to 4 days). 
IVDH was detected in all of the dogs (Table 2), and 
diffuse abnormal signal intensities were evident in 
the spinal cord at the site of IVDH. The T1WI of 
the affected areas revealed isointense signals that 
were absent in healthy spinal cords, whereas 
 hyperintense signals were detected on T2WI 
(Figure 1). The length of abnormal hyperintensity
Table 1 Clinical characteristics of dogs with confirmed or presumptive PM
Dog No. Breed Age (y) Sex BW (kg) Nociception CRP  (mg/dl) WBC  ( l) BT  CC  ) pNF-H 
(ng/ml)
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
   French Bulldog 
American Cocker Spaniel 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund 
 Miniature Dachshund
12 
4 
3 
3 
5 
4 
2 
2 
6 
5 
4 
11 
6 
6 
5 
3 
3 
3 
6 
7
M 
M 
M 
F 
M 
M 
M 
F 
F 
F 
M 
F 
F 
M 
M 
M 
M 
F 
F 
F
5.9 
3.7 
5.7 
8.1 
4.9 
5.6 
14 
13 
3.4 
5.6 
7.4 
5.5 
5.8 
5.2 
4.7 
6.1 
4.5 
4.9 
5.1 
4.4
0 
4.2 
0.45 
0 
0 
0.65 
0.25 
0 
1.1 
0.8 
0 
0 
0 
0.4 
0 
0 
0 
0 
0 
0
10500 
18700 
13000 
21700 
19000 
14600 
17900 
18700 
14900 
9400 
20800 
16700 
10100 
25500 
11500 
8700 
12500 
11800 
9100 
10500
38.9 
38.8 
38.6 
39.7 
38.6 
39.2 
39.8 
39.4 
38.5 
38.6 
39.2 
38.6 
38.9 
39.5 
38.7 
38.8 
38.4 
38.7 
38.6 
38.8
8.11 
6.76 
9.88 
7.15 
6.45 
8.76 
9.01 
6.43 
5.65 
9.54 
9.12 
8.99 
9.71 
9.59 
0 
0 
0 
0 
0 
0
C  =  Confirmed (based on necropsy or gross surgical inspection). CRP  =C-reactive protein. F  =Female. 
temperature. WBC  = White blood cell.  pNF-H= phosphorylated axonal neurofilament subunit H. 
-  =  Absent. +  =  Present. 
PM: Dog Nos. 1-14. 
Healthy: Dog Nos. 15-20.
 M=  Male. BW  =Body  weight. BT  =Body
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Table 2 Findings of MRI and neurologic signs in dogs with confirmed or presumptive PM
Dog No. Site of IVDH
Length of signal 
 hyperintensity"'
Interval between onset of 
clinical signs and MRI (d)
 SEP')
 Horner 
syndrome
 Survival 
duration (d) Diagnosis
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14
T13-L1 
T12-13 
T12-13 
T13-L1 
T13-L1 
T11-12 
 L2-3 
T13-L1 
T13-L1 
T13-L1 
T13-L1 
 L1-2 
 L1-2 
T12-13
2 
3 
NR 
1.5 
NR 
NR 
NR 
5 
NR 
4 
9 
NR 
0 
0
2 
2 
NR 
2 
 NR 
 NR 
NR 
4 
NR 
2 
3 
 NR 
1 
1
NR 
NR 
NR 
NR 
NR 
NR
6 
8 
6 
6 
8 
5 
3 
14 
13 
6 
6 
6 
9 
8
P 
C 
C 
C 
P 
P 
P 
P 
P 
C 
C 
C 
P 
P
a) Expressed as multiples of the length of the body of L2 at the site of  IVDH. b) Somatosensory evoked potential. 
C = Confirmed (based on necropsy or gross surgical inspection). IVDH  = Intervertebral disk  herniation. NR  = Not 
(based on characteristic clinical signs of PM). 
—  =Absent . +  =Present. 
Euthanasia: Dog Nos.  2,  4, 10, 12.
recorded.  P  =  Presumptive
                                                "
Dog No8.
Dog  No8.
 T1WI
T2WI
                                  
° 
          T1wI  Dog No11 .
Dog  No11.  T2WI
Fig. 1 Magnetic resonance imaging.  1'1-weighted and T2-weighted images of Dog No. 8 and Dog No. 
 11. In the T2-weighted image of Dog No. 8, the length of signal  hyperintensity was 5 times that 
of L2. In the T2-weighted image of Dog No.  11, the length of signal hyperintensity was 9 times 
that of L2.
Table 3 Monoclonal antibodies used in the present study
Phenotype Specificity Host Isotype Conjugate Clone
CD21 
CD3 
CD4 
CD8 
 NC' 
NC
    B-cells 
    T-cells 
 Helper T-cells 
Cytotoxic T-cells 
 Mouse  IgG1 
 Mouse  IgG1
Mouse 
Mouse 
 Rat 
 Rat 
Mouse 
Mouse
 IgG1 
 IgG1 
IgG2a 
 IgG1 
 IgG1 
 IgG1
 RPE  a) 
FITC 
RPE 
RPE 
FITC
 CA2.  1D6 
 CA17.  2Al2 
 YKIX302.  9 
 YCATE55.  9 
DAK-G01 
DAK-G01
a) RPE, Rhodophyceae phycoerythrin; b) FITC, Fluorescein isothiocyanate isomer I; c) Negative control. 
Antibody concentrations: As in manual.
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of the spinal cord on sagittal T2WI ranged from 
approximately 0 to 9 times that of thelumbar (L2) 
vertebral body.
Somatosensory evoked potential 
 Somatosensory evoked potential amplitudes 
were undetectable in the pelvic limbs of all dogs.
Flow cytometric analysis of peripheral blood 
 Peripheral blood was analyzed by flow cyto-
metry to determine the ratios of surface antigen 
markers. In PM dogs, the median relative rates 
(all % Values = tares) of surface markers were as 
follows : 76.0%  CD3+ (ranging from 69.9 to 83.0%), 
6.7% CD21  + (3.1 to 11.5%), 55.9% CD4  + (46.0 to 
65.0%), and 17.8% CD8  + (13.4 to 27.7%). The 
median  CD4+/CD8 + ratio was 3.2 (ranging from 
1.8 to 4.8) (Table 4). Comparatively, the median 
relative ratios of surface markers in healthy dogs 
were as follows: 73.6% CD3  + (ranging from 70.3 
to 80.7%), 7.2% CD21  + (5.9 to 15.7%), 46.8% CD4+ 
(39.2 to 54.1%), and 24.3% CD8 + (21.4 to 28.7%). 
The median  CD4  +/CD8  + ratio was 1.84 (ranging 
from 1.66 to 2.39). PM dogs exhibited significantly 
higher peripheral  CD4+ /CD8  + ratios compared 
with healthy dogs (p < 0.001).
Quantification of serum pNF-H levels 
 pNF-H was detected in the peripheral blood of 
all PM dogs, and the mean concentration was 8.23 
 ±  1.39 (SD) ng/mL. However, pNF-H was not 
detected in the blood of 6 healthy control beagles. 
The concentration of peripheral pNF-H levels in 
PM dogs was significantly different from that of 
the controls (p < 0.001).
Discussion 
 This is the first study to examine T lymphocyte 
phenotypes and pNF-H levels in the peripheral 
blood of dogs with PM. 
 The manifestation of clinical signs of PM  indi-
cates imminent death.  Horner syndrome, which 
was identified in 8 (57.1%) of the 14 dogs in this 
study, is one of the clinical symptoms unique to 
PM. The appearance of this syndrome indicates 
that the ascending progressive neuropathy has 
moved along the spinal cord and reached the head 
and thoracic region. All dogs that developed 
 Horner syndrome died within a few days. Veteri-
narians should thus inform owners of the impend-
ing death of their animals when PM is suspected 
based on evidence of  Horner syndrome. 
 In dogs with PM, T2WI MRI of the spinal cord
Table 4 Phenotypes on T lymphocytes in dogs with confirmed or presumptive PM
Dog No.
 CD3+ 
lymphocytes*
 CD21+(CD3-) 
lymphocytes*
 CD4+(CD8-) 
lymphocytes*
 CD8+(CD4-) 
lymphocytes*
 CD4+/CD8+ 
   ratio
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20
69.9 
75.8 
79.6 
76.7 
70.1 
80.4 
80.7 
75.8 
70.5 
76.2 
78.7 
83.0 
74.1 
70.8 
72.1 
76.8 
76.1 
70.9 
71.5 
72.2
10.0 
5.3 
3.1 
10.9 
8.0 
3.1 
5.9 
5.3 
11.5 
7.4 
3.7 
8.9 
5.9 
8.2 
6.8 
6.6 
9.4 
12.1 
11.9 
7.8
49.7 
50.6 
65.0 
62.0 
64.1 
63.7 
51.1 
50.6 
55.1 
60.0 
58.9 
56.7 
49.5 
46.0 
46.9 
48.7 
44.3 
47.1 
44.5 
48.1
19.8 
14.2 
20.6 
16.2 
13.4 
14.6 
27.7 
20.2 
20.6 
15.7 
18.2 
17.1 
17.6 
18.0 
27.2 
25.1 
22.9 
23.1 
22.9 
23.8
2.51 
3.56 
3.16 
3.83 
4.78 
4.36 
1.84 
2.50 
2.67 
3.82 
3.24 
3.32 
2.81 
2.55 
1.72 
1.94 
1.93 
2.04 
1.94 
2.02
*  Values are given in percentages
. 
PM: Dog Nos. 1-14. 
Healthy: Dog Nos. 15-20.
8
TAMURA et  al  : Clinical study of progressive myelomalacia
typically shows hyperintensity. Okada et al. re-
ported that T2 signal hyperintensity with a length 
6 to 20 times that of the L2 vertebral body was 
observed on MRI of all 12 PM animals examined 
(Okada et al.2010). In our study, T2 signal hyper-
intensity was observed in 6 of 8 animals that 
underwent MRI. The length of the T2 signal 
hyperintensity ranged from 1.5 to 9 times that of 
the L2 vertebral body (Table 2), and only 1 animal 
showed a T2 signal hyperintensity with a length 
of more than 6 times that of the L2 vertebral body. 
The fact that our results differ from those re-
ported by Okada et al. is likely to be attributable 
to the difference in the elapsed time from the 
onset of clinical signs to MRI (Okada et al. 2010). 
The median interval between the onset of clinical 
signs and MRI was 2.0 days (ranging from 1 to 4 
days) in this study, whereas the interval was 3.7 
days (ranging from 2 to 7 days) in the study by 
Okada et al (2010). The MRI of 2 animals that did 
not exhibit T2 signal hyperintensity in our study 
was performed within 24 hours of the onset of 
paraplegia. Therefore, extensive T2 signal hyper-
intensity, which is considered to be a feature 
unique to PM, may not be a characteristic finding 
if MRI is performed soon after onset. 
 An acute elevation of serum CRP levels reflects 
of inflammation and progressive tissue damage 
(Ceron et al. 2005). CRP is currently used as an 
inflammatory marker to determine the prognosis 
associated with a number of neoplastic (Shimada 
et al. 2003) diseases, myocardial infarction, and 
stroke in humans (Clearfield et al. 2005; Winbeck 
et al. 2002). Several recent reports on CRP levels 
in dogs demonstrated elevated CRP levels associ-
ated with certain disease states, including inflam-
matory bowel disease (Jergens et al. 2003), 
immune-mediated arthritis (Moore et al. 1992), 
and autoimmune hemolytic anemia (Tecles et al. 
2005). However, because the rise in CRP was 
evident in only a few of the PM dogs in our study, 
it was deemed unsuitable as a specific diagnostic 
marker. 
 In dogs, SEP can be recorded on the scalp by ap-
plying electrical stimulation to peripheral nerves 
on the scalp. The recorded SEP waveform re-
flects the activation of the sensory cortex. How-
ever, in humans, the short-latency SEP recorded 
on the scalp by applying electrical stimulation 
yields several waveforms that are considered to 
be induced in the peripheral nerve, spinal cord, 
brain stem, and cerebral sensory cortex (Poncelet 
et al. 1993; Uzuka et al. 1995; Vanderzant et al. 
1989). The waveform amplitude can be reduced 
or lost in dogs by experimentally compressing the
spinal cord and blocking the blood supply to it 
(Okuno et al. 2005). Previously, we reported a loss 
of SEP amplitude in clinical cases of neurological 
grade 5 IVDH in dogs (Okuno et al. 2012). In this 
study, loss of the SEP amplitude was confirmed in 
all PM dogs, indicating that a complete lack of 
amplitude is also observed during SEP monitoring 
in PM dogs. 
 Flow cytometers are used to analyze cell sur-
face markers and can be functionally classified as 
either cell sorters, which have a monitor and can 
selectively isolate the cells of interest, or cell 
analyzers, which are only capable of monitoring 
cell surface markers. In this study, we utilized a 
cell analyzer to analyze T lymphocyte pheno-
types. T lymphocytes are classified into 2 major 
subsets: CD4+  (CD8  -) helper T lymphocytes and 
 CD8+  (CD4-) cytotoxic T lymphocytes. The ratio 
of the 2 subsets in the peripheral blood of adult 
dogs is very similar to that of humans (Faldyna et 
al. 2001; Moore et al. 1992). According to Harris 
et al., the CD4+ /CD8+ ratio is 1.7 in healthy 
humans (Harris et al. 1992), and, in our study, the 
median  CD4+/CD8+ ratio was 1.84 (ranging from 
1.66 to 2.39) in healthy dogs. Furthermore, the 
lymphocyte subset ratio in the peripheral blood in 
our study revealed similarities between dogs and 
humans. Therefore, we conclude that the periph-
eral blood lymphocyte subset ratios are very 
similar in healthy dogs and humans. Gulizia et  al. 
(1993) reported that the CD4+ /CD8+ ratio was 
significantly higher in human patients with 
immune-mediated diseases compared with that of 
healthy subjects. In our study, the elevated  CD4+ 
 /CD84+ ratio observed in 13 out of the 14 (92.9%) 
dogs with PM (Table 4) was significantly higher 
compared with that of healthy dogs (p < 0.001). 
These results suggest that the  CD4+/CD8+ ratio 
could be a new diagnostic criterion for canine PM 
and should be explored further in future research. 
We note that CD3 and CD21 are additional T 
lymphocyte cell surface markers that can also be 
used for characterization. 
 Monitoring certain biomarkers in the blood or 
cerebrospinal fluid may be effective for determin-
ing the severity and stage of PM. A number of 
proteins produced in neurons and glial cells, 
including S100B, neuron-specific enolase, myelin 
basic protein, and glial fibrillary acidic protein, 
have been proposed as biomarkers of central 
nerve damage from traumatic brain injury in 
humans (Berger et al. 2007; Honda et al. 2010). 
However, reports of functional biomarkers for 
canine PM have yet to be published. 
 A correlation between serum pNF-H levels and
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disease outcomes has been described in recent 
studies that employed an animal spinal cord injury 
model (Shaw et al. 1999) and patients with 
aneurysmal subarachnoid hemorrhage (Loy et al. 
2005). pNF-H is a major structural protein com-
plex of axons and detected in the plasma when 
axons are injured. Because the phosphorylated 
form is resistant to protease degradation, pNF-H 
functions as an effective marker to monitor the 
extent of the injury. The serum pNF-H concen-
tration reaches its peak 3 days after spinal cord 
injury, in contrast to other neuron-derived bio-
markers such as  S100B and neuron-specific 
enolase, the concentrations of which peak within 
24 hours after the injury (Loy et al. 2005; Shaw et 
al. 1999). Such changes in serum pNF-H levels 
over time appear to reflect the progressive loss of 
axons as a result of secondary damage. In experi-
ments using a rat spinal cord injury model, serum 
pNF-H levels correlated with the strength of the 
initial impact (primary insult) applied via a spinal 
cord impactor (Shaw et al. 1999). Based on these 
findings, we analyzed the serum pNF-H levels 
were in canine PM to examine whether pNF-H 
could serve as a biomarker. In our study, pNF-H 
was not detected in the peripheral blood of 
healthy animals but was clearly detected in the 
peripheral blood of all PM dogs. Correlations 
between serum pNF-H levels and the prognosis 
have already been reported in studies conducted 
in aneurysmal subarachnoid hemorrhage patients 
and amyotrophic lateral sclerosis patients (Boylan 
et al. 2009; Lewis et al. 2008). Further studies are 
required to verify whether the pNF-H concentra-
tion can be used as an effective clinical biomarker 
of PM. The establishment of pNF-H as a bio-
marker of PM may facilitate the development of 
new therapies and improve the prognosis associ-
ated with currently incurable PM.
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